Comments on: Whytorin? HHS Spends Millions On The Drug http://www.pharmalot.com/2009/11/whytorin-should-hhs-spend-millions-on-the-drug/ News, Comment and Conversation Fri, 10 Feb 2012 20:47:34 +0000 http://wordpress.org/?v=2.6.2 By: Paul http://www.pharmalot.com/2009/11/whytorin-should-hhs-spend-millions-on-the-drug/#comment-446142 Paul Thu, 19 Nov 2009 04:30:41 +0000 http://www.pharmalot.com/?p=19933#comment-446142 Exactly...and niacin has been shown to have no benefits on patients who are at goal with statins. Exactly…and niacin has been shown to have no benefits on patients who are at goal with statins.

]]> By: Batman http://www.pharmalot.com/2009/11/whytorin-should-hhs-spend-millions-on-the-drug/#comment-446066 Batman Wed, 18 Nov 2009 17:31:15 +0000 http://www.pharmalot.com/?p=19933#comment-446066 Why would anyone pay for a drug with no proven benefits? Just saying Why would anyone pay for a drug with no proven benefits? Just saying

]]> By: Paul http://www.pharmalot.com/2009/11/whytorin-should-hhs-spend-millions-on-the-drug/#comment-446056 Paul Wed, 18 Nov 2009 16:29:39 +0000 http://www.pharmalot.com/?p=19933#comment-446056 To my friends and defenders of Niaspan vs. zetia. "Niacin not beneficial in patients at goal with statins: NIA Plaque" This is exactly the same conclusion, expressed differently. Niacin does not help outcomes in patients already treated for LDL. And Niaspan is very expensive niacin. To my friends and defenders of Niaspan vs. zetia.
“Niacin not beneficial in patients at goal with statins: NIA Plaque”

This is exactly the same conclusion, expressed differently. Niacin does not help outcomes in patients already treated for LDL.

And Niaspan is very expensive niacin.

]]> By: Condor http://www.pharmalot.com/2009/11/whytorin-should-hhs-spend-millions-on-the-drug/#comment-446040 Condor Wed, 18 Nov 2009 15:07:11 +0000 http://www.pharmalot.com/?p=19933#comment-446040 In truth, it is only a matter of time -- time for the gears of the <a href="http://shearlingsplowed.blogspot.com/2009/11/senator-grassleys-letter-on-arbiter-6.html" rel="nofollow">machinery of the governmental reimbursement bureaucracy to fully-engage</a> -- before Vytorin/Zetia is a Tier III drug, or dropped to the lowest tier of reimbursement, and thus assigned the highest level of out-of-pocket co-pay -- often over 70 percent for Tier III drugs. Inother words, the consumer will pay over 70% of the cost for a drug that costs ten times what a generic statin, plus niacin, does. . . . I hat-tiiped your PDF of letter -- thanks, Ed! Namaste In truth, it is only a matter of time — time for the gears of the machinery of the governmental reimbursement bureaucracy to fully-engage — before Vytorin/Zetia is a Tier III drug, or dropped to the lowest tier of reimbursement, and thus assigned the highest level of out-of-pocket co-pay — often over 70 percent for Tier III drugs. Inother words, the consumer will pay over 70% of the cost for a drug that costs ten times what a generic statin, plus niacin, does. . . .

I hat-tiiped your PDF of letter — thanks, Ed!

Namaste

]]>